The present invention is directed to novel kinase inhibitors of general formula (I) and pharmaceutically acceptable salts thereof, and to the use of the kinase inhibitors of general formula (I) for treating diseases or disorders in which tau phosphorylati
-
Page/Page column 55-57
(2011/04/24)
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
Cyanoguanidine quinazoline and cyanoamidine quinazolamine derivatives that are useful in the treatment of hyperproliferative diseases are disclosed. Methods of treating hyperproliferative diseases in mammals are also disclosed.
-
Page/Page column 10
(2008/06/13)
More Articles about upstream products of 697299-86-8